SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending as traders discuss Trump's potential executive action to reclassify marijuana, sparking hope for the cannabis sector. The community is debating the implications of rescheduling, potential short squeezes, and comparing TLRY to other cannabis stocks. Some are also expressing skepticism, citing past disappointments and the need for concrete action.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom's stock is experiencing volatility despite strong earnings, with analysts' target prices driving much of the current discussion. While the company beat expectations and offered positive guidance, some investors are taking profits, and others are concerned about future growth potential in non-AI sectors. The community is debating the sustainability of Broadcom's valuation and the impact of AI revenue projections.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members highlight its roots in cannabis culture and its presence on the Solana blockchain. Many are drawn to its positioning as a 'culture coin' with a focus on creativity and community building. Comparisons to Bitcoin are frequent, with the community emphasizing a vision of going 'way higher'.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors anticipate its Autonomy and AI Day, where the company is expected to reveal advancements in its self-driving technology and AI capabilities, with community chatter focusing on potential partnerships and the impact on competition with Tesla. Discussions also include analyst target price updates and debate over Rivian's valuation as a tech versus automotive company, alongside concerns about cash flow and production costs.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending after a Q3 earnings beat, raised full-year guidance, a CEO succession plan, and a buyback authorization, leading to analyst target price revisions. The community is discussing the potential for analyst upgrades and whether the stock can hold its gains amidst a challenging year. Some traders are pointing to strong execution, long-term visibility, and growth in China as reasons for renewed confidence.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to significant intraday volatility, with community members actively discussing a potential short squeeze and the impact of a recent conference. The stock's price swings are also influenced by its low float and sector momentum, particularly related to Bitcoin's movements. Some traders are wary of a potential offering and the company's compliance with listing requirements.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is gaining significant traction, fueled by community enthusiasm and its association with the Ethereum ecosystem. Discussions highlight its potential as a leading meme token and a beneficiary of renewed interest in ETH, with some even suggesting it could be the next PEPE. The community emphasizes strong fundamentals, a compelling narrative, and increasing accumulation from experienced traders.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

GLSI is trending due to anticipation surrounding an upcoming presentation and speculation about potential news, possibly at the SABCS conference. Community members are focused on the high short borrow rate and the possibility of a short squeeze, with some expressing FOMO and discussing technical indicators. The overall sentiment suggests a belief in the company's long-term potential, particularly regarding its breast cancer treatment.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amid discussions around its potential Nasdaq listing and speculation on new OEM partnerships as the Eagle Line facility inauguration in February 2026 approaches. The community is focused on the company's solid-state battery technology, its scaling roadmap, and expectations for near-term catalysts.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending as the community discusses recent investments in Ukrainian drone technology and potential benefits from increased defense spending. Bullish sentiment is fueled by the company's growing presence in the drone and counter-drone space, with speculation around upcoming announcements and price target increases. Traders are actively monitoring key price levels for breakout opportunities, and whether it could trigger a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alberta Investment Management Corp Buys Shares of 133,200 Zura Bio Limited $ZURA

Alberta Investment Management Corp bought a new position in Zura Bio Limited (NASDAQ:ZURA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and...

Chardan Capital Reiterates Buy Rating for Zura Bio (NASDAQ:ZURA)

Chardan Capital reissued a "buy" rating and issued a $10.00 price target on shares of Zura Bio in a report on Friday...

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Moderate Buy" by Brokerages

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst...

Wall Street Zen Downgrades Zura Bio (NASDAQ:ZURA) to Sell

Wall Street Zen lowered shares of Zura Bio from a "hold" rating to a "sell" rating in a research report on Sunday...

Zura Bio (NASDAQ:ZURA) Issues Earnings Results

Zura Bio (NASDAQ:ZURA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02...

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today...

Zura Bio (NASDAQ:ZURA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Zura Bio from a "sell" rating to a "hold" rating in a research report on Saturday...

Novartis (NVS) on Monday announced positive results from its late-stage trials evaluating its investigational drug Ianalumab in adults with active Sjögren's disease.Ianalumab is a novel fully human monoclonal antibody being investigated for its potential to treat various B-cell-driven autoimmune diseases. The drug’s mechanism of action targets B cells in two ways: combining B cell depletion and interruption of BAFF-R-mediated signals of B cell function and survival.Guggenheim said the positive updates give evidence that BAFF-signaling disruption and B cell depletion are "a valid approach" for hard-to-treat autoimmune diseases, which has a positive read-through for Zura Bio (ZURA). Shares of <a href="https://stocktwits.com/symbol/ZURA">Zura</a>, which Guggenheim deems "significantly undervalued," traded 3% higher at the time of writing.Novartis <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease">said</a> that its two late-stage trials for Sjögren's disease met the primary endpoint of demonstrating statistically significant improvements in disease activity. Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_12_02_03_PM_png_fdf22daf95.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure>Sjögren’s disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body. It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.“These Phase III studies mark a significant milestone. We look forward to engaging with health authorities to discuss these findings in the near future,” said Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis.Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease, the company said, while adding that it plans to submit the drug to health authorities globally.NYSE-listed shares of the company traded 1% higher at the time of writing.Ianalumab originated from Novartis’ early collaboration with MorphoSys AG, a company which it later acquired in 2024. In clinical trials, Ianalumab showed promising efficacy and a favorable safety profile in Sjögren’s disease, systemic lupus erythematosus, and immune thrombocytopenia.While NVS shares are up by 21% this year, ZURA is down 42%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/avantor-responds-to-activist-investor-engine-capital-letter/chru67IRde5">Avantor Responds To Activist Investor Engine Capital’s Letter: ‘Acting With Urgency To Strengthen Growth’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Equity

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.


Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Zura Bio Ltd - Ordinary Shares - Class A

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$4.04
Prev Close	$3.72
Open	$3.72
Dividend Yield	0.00%
50-Day Moving Average	$3.81
Beta	1.14
Avg. Volume	440,554.21
PE Ratio	-5.71

52-Week High	$4.68
52-Week Low	$0.97
Market Capitalization	$241.89M
EPS (Annual)	-$0.6046
Price to Book	2.43
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ZURA
Zura Bio Ltd - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZURA News

ZURAZura Bio Ltd - Ordinary Shares - Class A